| 國立臺灣大學 |
2012 |
Clinical Outcomes and Predictors for ESRD and Mortality in Primary GN
|
Chou, Yu-Hsiang; Lien, Yu-Chung; Hu, Fa-Chang; Lin, Wei-Chou; Kao, Chih-Chin; Lai, Chun-Fu; Chiang, Wen-Chih; Lin, Shuei-Liong; Tsai, Tun-Jun; Wu, Kwan-Dun; Chen, Yung-Ming; 賴俊夫; 陳永銘; 林維洲; 姜文智; 吳寬墩; 蔡敦仁; 林水龍 |
| 臺大學術典藏 |
2019-02-20T01:56:16Z |
Clinical outcomes and predictors for ESRD and mortality in primary GN
|
Yu-Hsiang Chou;Lien, Yu-Chung;Hu, Fu-Chang;Wei-Chou Lin;Kao, Chih-Chin;Lai, Chun-Fu;Chiang, Wen-Chih;Lin, Shuei-Liong;Tun-Jun Tsai;Wu, Kwan-Dun;Chen, Yung-Ming; YU-HSIANG CHOU; Lien, Yu-Chung; Hu, Fu-Chang; WEI-CHOU LIN; Kao, Chih-Chin; Lai, Chun-Fu; Chiang, Wen-Chih; Lin, Shuei-Liong; TUN-JUN TSAI; Wu, Kwan-Dun; Chen, Yung-Ming |
| 臺大學術典藏 |
2019-03-07T06:45:20Z |
Clinical outcomes and predictors for ESRD and mortality in primary GN
|
YU-HSIANG CHOU; Lien, Yu-Chung; Hu, Fu-Chang; WEI-CHOU LIN; Kao, Chih-Chin; Lai, Chun-Fu; Chiang, Wen-Chih; Lin, Shuei-Liong; TUN-JUN TSAI; Wu, Kwan-Dun; Chen, Yung-Ming; Yu-Hsiang Chou;Lien, Yu-Chung;Hu, Fu-Chang;Wei-Chou Lin;Kao, Chih-Chin;Lai, Chun-Fu;Chiang, Wen-Chih;Lin, Shuei-Liong;Tun-Jun Tsai;Wu, Kwan-Dun;Chen, Yung-Ming |
| 中山醫學大學 |
2010-10 |
Clinical outcomes and prognostic factors for patients with Vibrio vulnificus infections requiring intensive care: a 10-yr retrospective study
|
Chen, Shiuan-Chih; Chan, Khee-Siang; Chao, Wai-Nang; Wang, Po-Hui; Lin, Ding-Bang; Ueng, Kwo-Chang; Kuo, Sheng-Hung; Chen, Chun-Chieh; Lee, Meng-Chih |
| 中山醫學大學 |
2011 |
Clinical Outcomes and Prognostic Factors of Cancer Patients with Pyogenic Liver Abscess
|
Chen, Shiuan-Chih; Lee, Yuan-Ti; Tsai, Shih-Jei; Lai, Kuang-Chi; Huang, Chi-Chou; Wang, Po-Hui; Chen, Chun-Chieh; Lee, Meng-Chih |
| 中山醫學大學 |
2017-04 |
Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit
|
Dionysis, Papadatos-Pastos; Roda, Desam; Luken, Maria Jose De Miguel; Petruckevitch, Ann; Jalil, Awais; Capelan, Marta; Michalarea, Vasiliki; Joao Lima, Nikolaos Diamantis; Bhosle, Jaishree; Molife, L. Rhoda; Banerji, Udai; Bono, Johann S. de; Popat, Sanjay; O'Brien, Mary E.R.; Yap, Timothy A. |
| 臺大學術典藏 |
2018-09-10T18:02:57Z |
Clinical outcomes and prognostic factors of patients with severe influenza receiving intravenous peramivir salvage therapy in intensive care units
|
Yeh, C.-Y. and Wang, F.-D. and Chuang, Y.-C. and Yang, C.-J. and Huang, S.-F. and Weng, W.-S. and Liaw, C.-H. and Sheng, W.-H.; WANG-HUEI SHENG; YU-CHUNG CHUANG |
| 臺大學術典藏 |
2021-02-26T01:59:20Z |
Clinical outcomes and prognostic factors of patients with severe influenza receiving intravenous peramivir salvage therapy in intensive care units
|
Yeh C.-Y.;Wang F.-D.;Chuang Y.-C.;Yang C.-J.;Huang S.-F.;Weng W.-S.;Liaw C.-H.;Wang-Huei Sheng; Yeh C.-Y.; Wang F.-D.; Chuang Y.-C.; Yang C.-J.; Huang S.-F.; Weng W.-S.; Liaw C.-H.; WANG-HUEI SHENG |
| 臺大學術典藏 |
2020-12-29T03:48:03Z |
Clinical outcomes and prognostic factors of patients with severe influenza receiving intravenous peramivir salvage therapy in intensive care units
|
Yeh C.-Y.;Wang F.-D.;Yu-Chung Chuang;Yang C.-J.;Huang S.-F.;Weng W.-S.;Liaw C.-H.;Sheng W.-H.; Yeh C.-Y.; Wang F.-D.; YU-CHUNG CHUANG; Yang C.-J.; Huang S.-F.; Weng W.-S.; Liaw C.-H.; Sheng W.-H. |
| 臺大學術典藏 |
2019-03-04T06:50:19Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yang, James Chih Hsin;Lin, Zhong Zhe;Lee, Jih Hsiang;Yang, Ching Yao;Lin, Yen Ting;Chen, Kuan-Yu;CHONG-JEN YU;JIN-YUAN SHIH;CHIA-LIN HSU;CHAO-CHI HO;WEI-YU LIAO;JIN-SHING CHEN; Lin, Yen Ting; JIN-SHING CHEN; WEI-YU LIAO; CHAO-CHI HO; CHIA-LIN HSU; Yang, Ching Yao; Chen, Kuan-Yu; Lee, Jih Hsiang; Lin, Zhong Zhe; JIN-YUAN SHIH; Yang, James Chih Hsin; Chong-Jen Yu |
| 臺大學術典藏 |
2020-03-30T08:50:44Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.; Yang J.C.-H.; Shih J.-Y.; Lin Z.-Z.; Lee J.-H.; Chen K.-Y.; Yang C.-Y.; Hsu C.-L.; Ho C.-C.; Lin Y.-T.;Jin-Shing Chen;Liao W.-Y.;Ho C.-C.;Hsu C.-L.;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Lin Y.-T.; JIN-SHING CHEN; Liao W.-Y. |
| 臺大學術典藏 |
2020-05-20T05:11:42Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.;Yang J.C.-H.;Shih J.-Y.;Lin Z.-Z.;Lee J.-H.;Chen K.-Y.;Yang C.-Y.;Hsu C.-L.;Ho C.-C.;Liao W.-Y.;Chen J.-S.;YEN-TING LIN; YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T;Chen J.-S;Liao W.-Y;Ho C.-C;Hsu C.-L;Yang C.-Y;Chen K.-Y;Lee J.-H;Lin Z.-Z;Shih J.-Y;Chih-Hsin Yang;Yu C.-J.; Lin Y.-T; Chen J.-S; Liao W.-Y; Ho C.-C; Hsu C.-L; Yang C.-Y; Chen K.-Y; Lee J.-H; Lin Z.-Z; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:46:16Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.; Chen J.-S.; Liao W.-Y.; CHAO-CHI HO; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-08-12T02:50:37Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Hsu C.-L.; CHAO-CHI HO; Liao W.-Y.; Chen J.-S.; Lin Y.-T.; Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Chao-Chi Ho;Hsu C.-L.;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J. |
| 臺大學術典藏 |
2020-08-12T06:34:19Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Ho C.-C.;Hsu C.-L.;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Chong-Jen Yu; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; CHONG-JEN YU; Lin Y.-T.; Chen J.-S.; Liao W.-Y. |
| 臺大學術典藏 |
2020-08-13T06:33:27Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yang J.C.-H.; Yu C.-J.; JIN-YUAN SHIH; Lin Z.-Z.; Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H. |
| 臺大學術典藏 |
2020-07-21T06:09:04Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.; Shih J.-Y.; Yang J.C.-H.; Lin Z.-Z.; Lee J.-H.; Chen K.-Y.; Yang C.-Y.; Hsu C.-L.; Ho C.-C.; WEI-YU LIAO; Chen J.-S.; Lin Y.-T. |
| 臺大學術典藏 |
2020-12-24T03:18:47Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Ho C.-C.;Chia-Lin Hsu;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; CHIA-LIN HSU; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T02:38:31Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Anonymous |
| 臺大學術典藏 |
2022-02-21T03:52:33Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; JIH-HSIANG LEE; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T05:08:51Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Ho C.-C.;Hsu C.-L.;Yang C.-Y.;Kuan-Yu Chen;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; KUAN-YU CHEN; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-11T03:46:37Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; ZHONG-ZHE LIN; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-06-10T06:10:58Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; ZHONG-ZHE LIN; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-06-27T06:59:53Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; CHONG-JEN YU |
